Accredited Continuing Medical Education Huntington's Disease Symptoms, Diagnosis, Treatment, and Related Conditions

Huntington's Disease Symptoms, Diagnosis, Treatment, and Related Conditions

Short name: Huntington's Disease
Course start date: 06-10-2024
Course end date: 06-10-2026
Free Web-based Accredited CME / Huntington's Disease / Diagnosis & Treatment

Description

Provided by Parkinson & Movement Disorder Alliance

This session equips healthcare providers with the essential knowledge to identify Huntington's Disease (HD) and its differential diagnoses, understand and apply current and emerging treatments, and coordinate a multidisciplinary care team for optimal patient outcomes. Participants will gain confidence in diagnosing HD, utilizing referrals effectively, and integrating a collaborative approach to patient care.

Estimated time to complete activity: 75 minutes


Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.


Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss HD history and pathophysiology
  • Analyze recent treatment modalities for HD
  • Categorize pharmacological treatment options for HD symptoms
  • Appraise treatment algorithms for HD symptoms
  • Assess clinical research in HD

Faculty

Clarisse Goas, NP
The Ohio State University Wexner Medical Center

Clarisse Goas, APRN-CNP is a Nurse Practitioner who graduated Summa Cum Laude with Research Distinction from The Ohio State University in 2008 with a Bachelor of Science in Psychology. She graduated in 2012 with her MSN in Adult Health after receiving the Health Resources and Services Administration (HRSA) Award. She worked for 4 years at Pickaway Health Services in Primary Care. Her father’s diagnosis of Parkinson’s disease contributed to her desire to subspecialize in Movement Disorders. She worked for 4 years at Wake Forest Baptist Health treating Movement Disorders patients. She returned to Ohio in 2019 and joined The Ohio State University Wexner Medical Center in the Advanced Therapies Movement Disorders program in January of 2020. She has experience in clinical trials, (both as the principal investigator and co-investigator) including new medication symptomatic interventions, deep brain stimulation (Medtronic, Boston Scientific, Abbott) and intestinal pump drug delivery systems. She currently runs the virtual quarterly PD patient education series “Understanding the Disease,” is the PD Multidisciplinary Clinic Coordinator at OSU and the NP team lead for Duopa.  


Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

  • Clarisse Goas, NP
    • Principal or site investigator for research supported by Prilenia Therapeutics

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

  • Leslie Cloud, MD
    • Site investigator for research supported by Cereval Therapeutics, Bukwang Pharmaceutical, UCB Pharma, and Intracellular Therapies
    • Speakers’ Bureau, consultant, and/or advisory board member for Kyowa Kirin and AbbVie
  • Britt Stone, MD
    • Consultant or advisory board for Boston Scientific
  • Jason Rivera, MPH
    • No disclosures to report
  • Anissa Mitchel, LCSW
    • No disclosures to report
  • Kelly Papesh, DNP
    • Speakers’ Bureau, consultant, and/or advisory board member for Acadia, Amneal, and Supernus 

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 


Accreditation Statement

ACCME LogoIn support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Commercial Support

This activity is supported by independent medical education grants from Acadia, Merz, AbbVie, Kyowa Kirin, and Ipsen.


Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org


Sections

Educational Objectives
0 activities

Pre Test
Presentation
View Slide Deck
Post Test
Evaluation Survey: Huntington's Disease Symptoms, Diagnosis, Treatment, and Related Conditions
Completed "Huntington's Disease Symptoms, Diagnosis, Treatment, and Related Conditions" with PMD Alliance CME Program

Quiz Quiz
2
Video Video
1
File File
1
Questionnaire Questionnaire
1
Certificate Certificate
1

Instructors

Tag

Diagnosis Huntington's Treatment